Thelansis

Becker Muscular Dystrophy (BMD) Market Outlook Thelansis’s “Becker Muscular Dystrophy (BMD) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Becker Muscular Dystrophy (BMD) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). Key business questions answered: How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)? How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments? What is the 10-year market outlook for sales and patient share? Which events will have the greatest impac...

Becker Muscular Dystrophy (BMD) Market Outlook Thelansis’s “Becker Muscular Dystrophy (BMD) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Becker Muscular Dystrophy (BMD) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). Becker Muscular Dystrophy (BMD) Overview Becker muscular dystrophy (BMD) is an X-linked recessive allelic muscular dystrophy caused by mutations in the DMD gene. BMD is characterised by less severe clinical phenotypes than DMD, with onset mostly during school age, between 5-15 years old, even though there are several reported cases of late-onset BMD in the third and fourth decades of life. BMD clinical phenotyp...

  Becker muscular dystrophy (BMD) is an X-linked recessive allelic muscular dystrophy caused by mutations in the DMD gene. BMD is characterised by less severe clinical phenotypes than DMD, with onset mostly during school age, between 5-15 years old, even though there are several reported cases of late-onset BMD in the third and fourth decades of life. BMD clinical phenotypes are varied, ranging from mild symptoms, such as muscle cramps, myalgia, myoglobinuria and mild myopathy, to severe myopathy that can interfere with patient's ability to walk. Cardiac involvement has been reported in 70% of BMD cases. The most common type of cardiac abnormality is dilated cardiomyopathy, which is associated with congestive heart failure and premature death. The incidence of Becker muscular dystrophy (BMD) has been estimated to be between 1 in 18,000 and 1 in 30,000 male births. The prevalence of BMD is estimated to be 17 to 27 cases per million people. Female carriers of X-lin...